- Home
- TCRX vs RDZN Comparison
TCRX vs RDZN Comparison
Compare TCRX & RDZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- RDZN
- Stock Information
- Founded
- TCRX 2018
- RDZN 2015
- Country
- TCRX United States
- RDZN United States
- Employees
- TCRX N/A
- RDZN N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- RDZN Blank Checks
- Sector
- TCRX Health Care
- RDZN Finance
- Exchange
- TCRX Nasdaq
- RDZN Nasdaq
- Market Cap
- TCRX 90.5M
- RDZN 79.4M
- IPO Year
- TCRX 2021
- RDZN N/A
- Fundamental
- Price
- TCRX $1.38
- RDZN $0.77
- Analyst Decision
- TCRX Strong Buy
- RDZN Strong Buy
- Analyst Count
- TCRX 7
- RDZN 2
- Target Price
- TCRX $9.86
- RDZN $5.00
- AVG Volume (30 Days)
- TCRX 396.8K
- RDZN 236.1K
- Earning Date
- TCRX 05-06-2025
- RDZN 07-01-2025
- Dividend Yield
- TCRX N/A
- RDZN N/A
- EPS Growth
- TCRX N/A
- RDZN N/A
- EPS
- TCRX N/A
- RDZN N/A
- Revenue
- TCRX $4,421,000.00
- RDZN $42,893,256.00
- Revenue This Year
- TCRX $47.30
- RDZN $4.52
- Revenue Next Year
- TCRX $74.30
- RDZN $53.72
- P/E Ratio
- TCRX N/A
- RDZN N/A
- Revenue Growth
- TCRX N/A
- RDZN 2.79
- 52 Week Low
- TCRX $1.02
- RDZN $0.71
- 52 Week High
- TCRX $9.69
- RDZN $4.43
- Technical
- Relative Strength Index (RSI)
- TCRX 42.86
- RDZN 40.17
- Support Level
- TCRX $1.32
- RDZN $0.68
- Resistance Level
- TCRX $1.65
- RDZN $1.01
- Average True Range (ATR)
- TCRX 0.13
- RDZN 0.12
- MACD
- TCRX -0.01
- RDZN -0.02
- Stochastic Oscillator
- TCRX 14.63
- RDZN 22.73
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform global auto insurance powered by advanced AI. Its clients comprise major insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.